



A commentary by Mark C. Lee, MD, is linked to the online version of this article at jbjs.org.

Randomized Trial of Sacroiliac Joint Arthrodesis Compared with Conservative Management for Chronic Low Back Pain Attributed to the Sacroiliac Joint

Julius Dengler, MD, Djaya Kools, MD, Robert Pflugmacher, MD, Alessandro Gasbarrini, MD, Domenico Prestamburgo, MD, Paolo Gaetani, MD, Daniel Cher, MD, Eddie Van Eeckhoven, PharmD, Mårten Annertz, MD, PhD, and Bengt Stuesson, MD, PhD

Background: Sacroiliac joint pain is increasingly recognized as a cause of low back pain. We compared the safety and effectiveness of minimally invasive sacroiliac joint arthrodesis using triangular titanium implants and conservative management in patients with chronic sacroiliac joint pain.

Methods: This study was a prospective, multicenter randomized controlled trial of adults with chronic sacroiliac joint pain assigned to either conservative management or sacroiliac joint arthrodesis with triangular titanium implants. The study end points included self-rated low back pain (visual analog scale [VAS]), back dysfunction (Oswestry Disability Index [ODI]), and quality of life. Ninety percent of subjects in both groups completed the study.

Results: Between June 6, 2013, and May 15, 2015, 103 subjects were randomly assigned to conservative management (n = 51) or sacroiliac joint arthrodesis (n = 52). At 2 years, the mean low back pain improved by 45 points (95% confidence interval [CI], 37 to 54 points) after sacroiliac joint arthrodesis and 11 points (95% CI, 2 to 20 points) after conservative management, with a mean difference between groups of 34 points (p < 0.0001). The mean ODI improved by 26 points (95% CI, 21 to 32 points) after sacroiliac joint arthrodesis and 8 points (95% CI, 2 to 14 points) after conservative management, with a mean difference between groups of 18 points (p < 0.0001). Parallel improvements were seen in quality of life. In the sacroiliac joint arthrodesis group, the prevalence of opioid use decreased from 56% at baseline to 33% at 2 years (p = 0.009), and no significant change was observed in the conservative management group (47.1% at baseline and 45.7% at 2 years). Subjects in the conservative management group, after crossover to the surgical procedure, showed improvements in all measures similar to those originally assigned to sacroiliac joint arthrodesis. In the first 6 months, the frequency of adverse events did not differ between groups (p = 0.664). By month 24, we observed 39 severe adverse events after sacroiliac joint arthrodesis, including 2 cases of sacroiliac joint pain, 1 case of a postoperative gluteal hematoma, and 1 case of postoperative nerve impingement. The analysis of computed tomographic (CT) imaging at 12 months after sacroiliac joint arthrodesis showed radiolucencies adjacent to 8 implants (4.0% of all implants).

continued

Disclosure: The study was funded by SI-BONE (Santa Clara, California), the manufacturer of the iFuse Implant System used in the study. One author of this study (D.C.) is an employee at SI-BONE. Four authors (D.K., R.P., E.V.E., and B.S.) are consultants to SI-BONE. The study sponsors participated in study design, data collection, data analysis, data interpretation, and writing of the report. One author of this study (J.D.) had full access to all study data and had final responsibility for the decision to submit for publication. Study data are available through the Yale University Open Data Access (YODA) data-sharing program. The **Disclosure of Potential Conflicts of Interest** forms are provided with the online version of the article. (<http://links.lww.com/JBJS/F143>).

Copyright © 2019 The Authors. Published by The Journal of Bone and Joint Surgery, Incorporated. All rights reserved. This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non Commercial-No Derivatives License 4.0](https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Conclusions: For patients with chronic sacroiliac joint pain due to joint degeneration or disruption, minimally invasive sacroiliac joint arthrodesis with triangular titanium implants was safe and more effective throughout 2 years in improving pain, disability, and quality of life compared with conservative management.

Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

Low back pain is the number-1 contributor to global health burden in terms of years lived with disability¹. Chronic low back pain is the most common specific reason for prescribed opioid use² and has contributed to marked increases in opioid abuse³. Finding effective solutions for chronic low back pain is a critical agenda item for health-care professionals worldwide.

Pain from the sacroiliac joint has long been recognized as a potential source of chronic low back pain, playing a role in 15% to 30% of patients with chronic low back pain⁴⁻⁶. Also, the sacroiliac joint is implicated in up to 40% of patients with new-onset low back pain after lumbar arthrodesis⁷.

The effectiveness of nonsurgical treatments for chronic sacroiliac joint pain remains unclear. Periarticular radiofrequency ablation and periarticular corticosteroid injections are supported only by short-term evidence; to our knowledge, no long-term, high-quality evidence supports these treatments' effectiveness. Open surgical arthrodesis of the sacroiliac joint can be achieved through multiple approaches⁸. With the advent of minimally invasive approaches, open arthrodesis of the sacroiliac joint has decreased in usage. The most studied minimally invasive sacro-

iliac joint arthrodesis device, triangular titanium implants, has evidence support from randomized trials^{9,10}, a multicenter single-arm trial¹¹, prospective case series¹²⁻¹⁵, and comparative case series¹⁶⁻¹⁸. We conducted a randomized trial of minimally invasive sacroiliac joint arthrodesis compared with conservative management, previously reporting short-term outcomes¹⁰. Herein, we report 2-year results.

Materials and Methods

iMIA (iFuse Implant System Minimally Invasive Arthrodesis; ISI-BONE) is a prospective, open-label, multicenter randomized controlled trial conducted at 9 European centers. Local ethics committees approved the protocol prior to study initiation. The trial was registered at ClinicalTrials.gov (NCT01741025). One-year results for iMIA were published previously¹⁹. Details on the study design are presented in the Appendix. In brief, subjects with clinically relevant pain originating from the sacroiliac joint were randomized to either conservative management or sacroiliac joint arthrodesis (Fig. 1). Subjects had scheduled follow-up visits to 24 months after randomization. Assessments, described previously, included




Fig. 1 Patient flow. SIJA = sacroiliac joint arthrodesis, CM = conservative management, FU = follow-up, m = month, X-over = crossover, and LTFU = lost to FU.

TABLE I Baseline Characteristics of Enrolled and Randomized Subjects

	Conservative Management (N = 51)	Sacroiliac Joint Arthrodesis (N = 52)	P Value*
Age† (yr)	46.7 (23 to 69)	49.4 (27 to 70)	0.210
Female sex‡	37 (72.5%)	38 (73.1%)	0.999
Pain duration† (yr)	4.5 (0.45 to 23)	4.9 (0.58 to 44)	0.777
BMI† (kg/m ²)	27.6 (16 to 44)	26.5 (18 to 42)	0.355
Smoking‡			0.044
Current	16 (31.4%)	23 (44.2%)	
Former	8 (15.7%)	14 (26.9%)	
Never	27 (52.9%)	15 (28.8%)	
Pain syndrome‡			
Pain began in peripartum period	3 (5.9%)	6 (11.5%)	0.488
Radiates down leg	40 (78.4%)	42 (80.8%)	0.811
Pain in groin	36 (70.6%)	31 (59.6%)	0.303
Pain sitting	38 (74.5%)	42 (80.8%)	0.486
Pain rising	40 (78.4%)	48 (92.3%)	0.055
Pain walking	42 (82.4%)	43 (82.7%)	0.999
Pain climbing stairs	41 (80.4%)	41 (78.8%)	0.999
Pain descending stairs	29 (56.9%)	33 (63.5%)	0.549
Prior treatment‡			
Prior physical therapy	27 (52.9%)	32 (61.5%)	0.429
Prior prolotherapy	0 (0%)	0 (0%)	0.999
Prior corticosteroid sacroiliac joint injections	38 (74.5%)	37 (71.2%)	0.825
Prior radiofrequency ablation§	6 (11.8%)	11 (21.2%)	0.289
Work status‡			0.792
Working normal hours	3 (5.9%)	5 (9.6%)	
Working with limitations	12 (23.5%)	13 (25.0%)	
Not working due to lower back pain	27 (52.9%)	23 (44.2%)	
Not working due to other reason	2 (3.9%)	1 (1.9%)	
Retired	7 (13.7%)	10 (19.2%)	
Ambulatory status‡			0.295
Ambulatory without assistance	46 (90.2%)	42 (80.8%)	
Ambulatory with assistance	3 (5.9%)	8 (15.4%)	
Cannot walk	2 (3.9%)	2 (3.8%)	
History of prior lumbar arthrodesis‡	19 (37.3%)	18 (34.6%)	0.839

*The Fisher test was used to determine p values for nominal variables, and the t test was used to determine p values for continuous variables.

†The values are given as the mean, with the range in parentheses. ‡The values are given as the number of patients, with the percentage in parentheses. §This is radiofrequency ablation of the lateral branches of the sacral nerve root.

changes in low back pain (visual analog scale [VAS] for pain), leg pain, active straight leg raise for the affected side²⁰, Oswestry Disability Index (ODI)²¹, EuroQoL EQ-5D²², and Zung Depression Scale²³. In the sacroiliac joint arthrodesis cohort, computed tomographic (CT) scans were conducted immediately postoperatively and at 12 months.

Statistical Analysis

The minimum sample size was 40 subjects in each group, providing a power of 80% to identify a difference of 20 VAS points in sacroiliac joint pain with the assumption of a standard deviation of

35 points. Accounting for expected loss to follow-up, the trial's sample size was inflated to 50 per group. T tests and repeated-measures analysis of variance were used to compare continuous variables. Ordinal end points were analyzed using the Wilcoxon test, logistic or proportional-odds logistic regression, or the McNemar test for paired observations. Poisson regression was used to compare the number of adverse events per subject across groups. The primary end point used an as-available data analysis approach without missing data imputation. The impact of crossover from conservative management to sacroiliac joint arthrodesis was investigated using a last-observation-carried-forward

TABLE II Description of Operative Characteristics (Index Side Only) and Conservative Management

Study Group	Value
Sacroiliac joint arthrodesis (n = 52)	
Time from enrollment to surgery* (days)	18 (1 to 82)
No. of implants†	
3	51 (98.1%)
4	1 (1.9%)
Procedure duration* (min)	54 (19 to 107)
Fluoroscopy time* (min)	2.1 (1.0 to 4.0)
Hospital length of stay* (days)	3 (1 to 28)
Conservative management (n = 51)	
Physical therapy sessions†	
1	1 (2.0%)
2 to 4	2 (3.9%)
5 to 10	1 (2.0%)
11 to 15	9 (17.6%)
>15	38 (74.5%)
Cognitive behavioral therapy sessions†	
0	27 (52.9%)
1	1 (2.0%)
2 to 5	7 (13.7%)
6 to 10	10 (19.6%)
11 to 15	3 (5.9%)
>15	3 (5.9%)

*The values are given as the median, with the range in parentheses. †The values are given as the number of patients, with the percentage in parentheses.

approach, substituting the last observation prior to crossover for subsequent values. Repeated-measures analysis of variance was used to compare all post-treatment change scores across the following subgroups: age, pain duration, relation to pregnancy, sex, body mass index (BMI), prior lumbar arthrodesis, use of opioids, and smoking. All statistical analyses were performed using R (The R Foundation)²⁴. All study data were 100% source-verified.

Results

Between June 6, 2013, and May 15, 2015, 109 qualified subjects were enrolled; of these, 6 (4 assigned to conservative management and 2 assigned to sacroiliac joint arthrodesis) withdrew before any intervention, leaving 103 participating subjects (Fig. 1). Baseline characteristics are displayed in Table I. The mean baseline low back pain scores were 77.7 points in the sacroiliac joint arthrodesis group and 73.0 points in the conservative management group ($p = 0.06$).

Of the subjects who underwent sacroiliac joint arthrodesis, 7 had bilateral pain and underwent staged bilateral sacroiliac joint arthrodesis, 11 had bilateral pain but underwent only unilateral sacroiliac joint arthrodesis, 6 with initial unilateral pain underwent bilateral sacroiliac joint arthrodesis, and the remainder underwent unilateral sacroiliac joint arthrodesis for unilateral

pain. All but 1 case used 3 implants on the treated side (Table II); in the remaining subject, 4 implants were used on the treated side. The median hospital length of stay was 3 days (range, 1 to 28 days). Subjects assigned to conservative management underwent a mean of 25 physical therapy sessions over the first 6 months. Two subjects in the conservative management group underwent sacroiliac joint corticosteroid injections and 1 subject underwent sacroiliac joint corticosteroid injection and radiofrequency ablation as deviations from the investigational protocol.

Low back pain improvement at 6 months was significantly larger in the sacroiliac joint arthrodesis group (43.3 points) compared with conservative management (5.7 points), a difference of 38 points ($p < 0.0001$) (Fig. 2). Improvement in low back pain after sacroiliac joint arthrodesis persisted at 24 months; the mean improvement was 45.3 points (95%




Fig. 2 Change in VAS low back (LB) pain, VAS leg pain, ODI, EQ-5D time trade-off (TTO), EQ-5D VAS, and Zung Depression Scale scores. Blue indicates the conservative management group, and green indicates the sacroiliac joint arthrodesis group. The last-observation-carried-forward method was used to estimate values after crossover. The values shown are the mean. The error bars indicate the 95% CI.




Fig. 3

Change in functional test (active straight leg raise test) by treatment and time (left) and the number of positive physical examination signs (right). Blue indicates the conservative management group, and green indicates the sacroiliac joint arthrodesis group. The solid line indicates the right sacroiliac joint affected, and the dotted line indicates the left sacroiliac joint affected. The last-observation-carried-forward method was used to estimate values after crossover. The values shown are the mean. The error bars indicate the 95% CI.

confidence interval [CI], 37 to 54 points), 34 points higher than the conservative management group ($p < 0.0001$). Improvements in leg pain paralleled those seen in low back pain, with minimal improvements in the conservative management group (by 1.4 points at 6 months and 7.7 points at 24 months) and large improvements (by 30 points at 6 months and 32 points at 24 months) in the sacroiliac joint arthrodesis group. In the conservative management group, the mean ODI improved minimally at 6 months (by 5.6 points) and 24 months (by 8 points); in contrast, the mean ODI improved rapidly in the sacroiliac joint arthrodesis group by 26 points (95% CI, 21 to 32 points) at 24 months. At 6 months, 79% (41 of 52) of subjects in the sacroiliac joint arthrodesis group had an improvement in low back pain by at least 20 VAS points compared with 22% (11 of 49) of subjects in the conservative management group. Twenty-four months after sacroiliac joint arthrodesis, 79% (37 of 47) had at least a 20-point improvement compared with 24% (11 of 46) in the conservative management group. Threshold 24-month improvements for the ODI occurred in 64% (30 of 47) in the sacroiliac joint arthrodesis group compared with 24% (11 of 46) in the conservative management group. Similar patterns were observed for the EQ-5D time trade-off, with large changes in the sacroiliac joint arthrodesis group at 6 months (0.37 point) and 24 months (0.39 point) and smaller changes in the conservative management group at 6 months (0.09 point) and 24 months (0.15 point). The mean Zung Depression Scale score showed no improvement in the conservative management group and a 5.3-point improvement in the sacroiliac joint arthrodesis group at 6 months, and this difference persisted at 24 months. All across-group comparisons reported here had p values of <0.001 . Subgroup analysis showed the following in the sacroiliac joint arthrodesis group at 6 months. Current smokers had a somewhat smaller decrease in VAS low back pain (38 points) compared with former smokers (52 points) and those who had never smoked (43 points); current smokers also had a somewhat

smaller decrease in the ODI (21 points) compared with former smokers (29 points) and those who had never smoked (30 points). Baseline opioid users also had somewhat smaller ODI responses (22 points) compared with non-users (28 points) but similar VAS low back pain reduction. The reduction in VAS low back pain was larger in patients with higher baseline back pain scores; similarly, ODI improvements were larger in those with higher baseline scores.

The active straight leg raise showed no significant improvement in the conservative management group but large improvements after sacroiliac joint arthrodesis ($p < 0.0001$ compared with baseline and $p < 0.0001$ compared with conservative management) (Fig. 3). Superior improvement in




Fig. 4

Proportion of subjects reporting opioid use in the past 2 weeks by treatment and study visit. Blue indicates the conservative management (CM) group, and green indicates the sacroiliac joint arthrodesis (SIJA) group.




Fig. 5-A

Figs. 5-A, 5-B, and 5-C Bar graphs showing outcomes after conservative management (CM) and sacroiliac joint arthrodesis (SIJA). The last-observation-carried-forward method was used to estimate values after crossover. **Fig. 5-A** Change in walking distance and ambulatory status.

the number of positive physical examination findings was also observed ($p < 0.0001$). The proportion of subjects using opioids decreased in the sacroiliac joint arthrodesis group from 56% at baseline to 33% at 24 months (McNemar $p = 0.009$) but was constant in the conservative management group ($p = 1$) (Fig. 4).

Additional outcomes, such as walking distance, global comparison with baseline, and overall satisfaction, were superior after sacroiliac joint arthrodesis compared with conservative management (Figs. 5-A, 5-B, and 5-C). In subjects in the sacroiliac joint arthrodesis group, work status improved significantly over time ($p = 0.001$).




Fig. 5-B

Change in work status and comparison with baseline.




Fig. 5-C

Change in satisfaction and desirability of having a surgical procedure again by treatment and follow-up visit.

Crossover

In the conservative management group, there was no early crossover to sacroiliac joint arthrodesis. After the 6-month visit, 21 subjects (43%) in the conservative management group crossed over to sacroiliac joint arthrodesis. Crossover subjects had similar baseline characteristics compared with subjects who did not cross over, with the exception of more leg pain and a higher proportion of opioid use (30% compared with 5%). Subjects who crossed over had higher 6-month low back pain, leg pain, and ODI scores compared with subjects who did not cross over. Additionally, subjects who crossed over at 6 months had almost no mean improvement in pain and the ODI by 6 months. In contrast, subjects who did not cross over had modest improvements in back pain and the ODI by 6 months. After crossover to sacroiliac joint arthrodesis, improvements in pain, disability, and quality of life were similar to those observed in subjects originally assigned to sacroiliac joint arthrodesis (Fig. 6).

Adverse Events

During the first 6 months (200 days), 20 adverse events occurred in 16 subjects in the sacroiliac joint arthrodesis group and 17 adverse events occurred in 15 subjects in the conservative management group (Table III). The rate of events prior to 6 months was similar across groups: 0.33 in the sacroiliac joint arthrodesis group compared with 0.38 in the conservative management group ($p = 0.6644$).

By 24 months, 39 events occurred in the sacroiliac joint arthrodesis group that were rated as severe. Of these, only 4 were probably or definitely related to the study device or procedure: 2 cases of increased sacroiliac joint pain, 1 case of gluteal hematoma, and 1 case of implant-related nerve root impingement causing radicular pain that resolved after a revision surgical

procedure. Severe events unrelated to the device or procedure included 14 events in the low back (e.g., disc herniation, lumbar facet pain), 3 events in the hip (e.g., trochanteric bursitis), 10 events in the pelvis (primarily sacroiliac joint or contralateral sacroiliac joint pain), and 8 events unrelated to the pelvis, spine, or hip. In the conservative management group, 27 severe adverse events were observed, of which only 1 was related to a study procedure. In this case, the subject had gluteal and leg pain after a crossover sacroiliac joint arthrodesis; CT showed implant loosening and the pain experienced by the subject responded to a repeat diagnostic sacroiliac joint block. A revision surgical procedure was performed with implant removal and intra-articular arthrodesis via a posteroinferior approach using screws.

Radiographic Analysis

Forty-three of 52 subjects in the sacroiliac joint arthrodesis group had an evaluable 12-month CT scan, providing information on 35 right sides and 31 left sides with a total of 198 implants. Representative CT imaging is shown in Figure 7. According to the independent radiologist reader, the following observations were made. There was no evidence of implant breakage or migration. Breaches (i.e., penetration of cortical margins) occurred in 17 (8.6%) of 198 implants, including 7 breaches into a sacral foramen. Breaches were more commonly observed in the caudal-most implant (11 cases).

Five implants (2.5%) showed radiolucency along a single side and 3 implants (1.5%) showed radiolucency along all 3 sides; none of these patients had clinical signs attributable to radiolucency. The majority of implants showed bone apposition to the implants on both the sacral and iliac sides of the sacroiliac joint (Fig. 8). Intra-articular fusion with bridging of trabeculae from ilium to sacrum was not commonly observed.




Fig. 6
Change in VAS low back (LB) pain, VAS leg pain, ODI, Zung Depression Scale, EQ-5D time trade-off (TTO), and EQ-5D VAS scores including subjects who crossed over from conservative management to sacroiliac joint arthrodesis. Green indicates the subjects initially assigned to sacroiliac joint arthrodesis, blue indicates subjects assigned to the conservative management group prior to crossover, and gray indicates conservative management subjects who crossed over to surgical treatment with the sacroiliac joint arthrodesis group after the 6-month visit. The values shown are the mean. The error bars indicate the 95% CI.

The mean implant engagement length (length from the distal end of the implant to the lateral sacral cortex) was approximately 25 to 28 mm for the first (cranial) implant and pro-

gressively decreased to 7 to 11 mm for the caudal-most implant (Table IV). There was no significant relationship between total implant engagement length and clinical responses.

TABLE III Adverse Events by Relationship to Study Device, Severity, Treatment, and Timing

Probably or Definitely Related to Study Device or Procedure	Event Timing*	Conservative Management Event Severity†			Sacroiliac Joint Arthrodesis Event Severity†		
		Mild	Moderate	Severe	Mild	Moderate	Severe
No	≤6 months	3	3	11	2	2	12
	>6 months	2	10	15	4	7	23
Yes	≤6 months	0	0	0	0	0	4
	>6 months	1	1	1	0	0	0
All events	All	6	14	27	6	9	39

*The time of 6 months corresponds to 200 days after assignment either to conservative management or sacroiliac joint arthrodesis. †The values are given as the number of adverse events.




Fig. 7
Imaging of typical configuration of implants. **Fig. 7-A** Inlet-view pelvic radiograph. **Fig. 7-B** A 12-month CT image from a different subject showing no radiolucencies around the first implant. **Fig. 7-C** A 12-month CT image from another subject showing radiolucency around the second implant in the sacrum.

Discussion

The results of this randomized controlled trial support sacroiliac joint arthrodesis with lateral transarticular placement of triangular titanium implants as a safe and effective treatment for chronic sacroiliac joint pain unresponsive to conservative management. Subjects undergoing sacroiliac joint arthrodesis experienced sustained improvements in multiple patient-reported parameters, including low back and leg pain, disability, and quality of life, as well as modest improvements in depression scores. Improvements were also seen in walking distance and work status. A unique feature of our study is the assessment of physical function, including the active straight leg raise test and repeat physical examination maneuvers that stress the sacroiliac joint, both of which showed improvements after sacroiliac joint arthrodesis but not after conservative management. In addition,

similar improvements in key parameters occurred in conservative management subjects who crossed over to sacroiliac joint arthrodesis. In contrast, conservative management provided little, if any, net improvement in any of these parameters, including pain, disability, quality of life, depression scores, ability to perform the active straight leg raise test, or number of positive physical examination maneuvers. These findings provide evidence of the intermediate-term superiority of sacroiliac joint arthrodesis over continued conservative treatments in a patient population with debilitating chronic sacroiliac joint pain.

Although all study patients had undergone at least 6 months of conservative management prior to enrollment, with persistence of pain and disability, only a small portion of conservative management subjects experienced improvements in pain during the study. Of interest, patients in the conservative management group who experienced a clinically important improvement in low back pain by 6 months showed improvement starting as early as the first 3 months. This finding suggests that the conservative management treatment effect can be judged relatively quickly. Also, the proportion of subjects with opioid use decreased only after sacroiliac joint arthrodesis but not after conservative management. Because low back pain is a frequent trigger for long-term opioid use, our results support the view that the current discussion on the detrimental epidemiological impact of opioid use ought to include alternatives to conservative management that may help to decrease the demand for opioids.

Subgroup analysis showed that current smokers had somewhat smaller low back pain and ODI improvements after sacroiliac joint arthrodesis compared with nonsmokers. However, smokers still derived clinically important benefits from the procedure. These results are consistent with a pooled analysis of data from the current study and 2 U.S. studies²⁵.

Radiographic analysis, based on 12-month CT scans, showed no evidence of device migration or breakage. Breaches (i.e., the presence of some aspect of the implant outside of the sacral cortex on CT scan) were mostly not associated with clinical



Fig. 8
A 12-month CT image depicting bilateral implants with bone apposition along the entire length of the superior and inferior sides of both implants. Also, there is bone overgrowth at the outer iliac cortex (the left side is greater than the right side), suggesting complete implant integration into the ilium. However, there is little bone apposition along the implants within the joint.

TABLE IV Postoperative Engagement Length by Implant Number, View, and Side Measured in Subjects Undergoing Sacroiliac Joint Arthrodesis

Implant Number	View (Side*)	No of Patients	Engagement Length† (mm)
1 (superior)	Axial (anterior)	64	27.3 ± 5.5 (16 to 41)
	Axial (posterior)	64	23.5 ± 6.1 (5 to 35)
	Coronal (superior)	63	27.9 ± 5.2 (15 to 44)
	Coronal (inferior)	63	25 ± 5.5 (13 to 42)
2	Axial (anterior)	64	19.2 ± 5.3 (9 to 36)
	Axial (posterior)	64	16 ± 5.2 (4 to 30)
	Coronal (superior)	63	18.7 ± 5.1 (7 to 32)
	Coronal (inferior)	63	16.3 ± 5 (7 to 28)
3	Axial (anterior)	63	16.1 ± 5.7 (5 to 36)
	Axial (posterior)	59	13.2 ± 5.9 (0 to 26)
	Coronal (superior)	62	15.6 ± 5.9 (1 to 33)
	Coronal (inferior)	61	14.1 ± 5.6 (0 to 32)
4 (caudal)	Axial (anterior)	1	11
	Axial (posterior)	1	8
	Coronal (superior)	1	10
	Coronal (inferior)	1	7

*The sides are determined as the anterior side of the implant on an axial view, the posterior side of the implant on an axial view, the superior side of the implant on a coronal view, and the inferior side of the implant on a coronal view. †The values for implants 1 to 3 are given as the mean and the standard deviation, with the range in parentheses; the values for implant 4 are given as the mean.

symptoms, with the exception of 1 subject with post-placement radicular pain that improved on surgical implant repositioning. Breach was more common in implants placed more caudally, confirming that caudal implant placement is more technically challenging. Symptomatic breaches typically manifest with immediate postoperative new neuropathic pain; in our study, late (12-month) CT scans did not show any breaches associated with new or recurrent symptoms. Radiolucencies occurred at a low frequency; no radiolucency seen by the independent radiologist was associated with new or recurrent symptoms. In 2 cases, radiolucencies seen by the investigator were associated with recurrent sacroiliac joint pain, and, in 1 case, a revision surgical procedure was performed to address apparent loosening of the implants. Implant engagement length into the sacrum was largest for the cranial-most implants and progressively decreased for the more caudal implants. Typically, the superior-most implant can be placed deeply into the sacral ala above the S1 neuroforamen. The sacral ala progressively narrows caudally and the presence of neuroforamina precludes deep implant placement for implants placed more caudally. Although increased total implant engagement length into the sacrum may improve sacroiliac joint stabilization, we were unable to demonstrate a significant relationship with clinical responses.

Binding of bone to implants within the sacrum and ilium was commonly seen; bridging bone, reflecting intra-articular fusion, which was not evaluated in our study, may take longer^{9,26}. However, in contrast to other joints that are surgically fused, the sacroiliac joint has very little inherent motion; our data sub-

stantiate that permanent stabilization with implants showing avid bone binding at 12 months results in excellent patient outcomes; whether maneuvers to accelerate fusion with obliteration of the sacroiliac joint improve patient outcomes is unclear.

No unanticipated adverse events occurred. The rate of revision surgical procedures in subjects undergoing sacroiliac joint arthrodesis (2 cases) was low and consistent with prior trials and analyses^{9,11,15,27,28}, which showed that the perforation of sacral nerve foramina rarely occurs after sacroiliac joint arthrodesis²⁷. In the literature, the revision rates after sacroiliac joint arthrodesis (3.4% at 4 years²⁷) are lower than after a lumbar spine surgical procedure (14% at 4 years²⁹).


Our findings are consistent with findings from a U.S. randomized trial⁹, a prospective U.S. single-arm study¹¹, and several retrospective cohorts¹²⁻¹⁸. The improvements that we observed in low back pain were also similar to those observed in patients in the Swedish Spine Register of various spine surgical procedures³⁰.

Our study has multiple strengths, including its multi-center design according to a uniform clinical protocol with a control group receiving maximal conservative management, a standardized diagnostic algorithm, similar implant placement configurations across participating study centers, and 2-year follow-up. The primary limitation of our study was a lack of subject and outcome assessor blinding, which would have been challenging because implants are radiopaque and preventing subjects from seeing their radiographic studies would have been impossible. The large effect sizes seen strongly argue against a marked contribution from placebo effects. Although our trial

followed nonsurgical European guidelines for the treatment of sacroiliac joint pain with intensive physical therapy provided, it is possible that more intensive conservative management might have provided somewhat better results. An additional limitation was the high crossover rate after 6 months. Finally, we note that our study utilized sacroiliac joint arthrodesis with a single system (triangular titanium implants); whether our results apply to other sacroiliac joint arthrodesis surgical approaches, systems, and devices is not known. Except for smoking status, baseline parameters were distributed evenly across treatment groups. Subjects assigned to sacroiliac joint arthrodesis were more likely to be smokers; if smoking reduces the rate of bone-healing, as is commonly accepted, the increased proportion of smokers in the sacroiliac joint arthrodesis group would have biased study results against sacroiliac joint arthrodesis. Post-randomization interventions or subject behaviors that could have impacted the study's results were not readily apparent; some subjects in the conservative management group received prolonged physical therapy, which theoretically could have increased its effect. The collection of information to support the calculation of health indices (e.g., Charlson Comorbidity Index³¹) and further opioid history during a 6-month period prior to the study start could also have been helpful. An analysis of predictors of response in the conservative management group is also of interest; however, our sample size was too small to accomplish this goal.

In conclusion, minimally invasive sacroiliac joint arthrodesis with triangular titanium implants was safe and effective at 2 years for the treatment of chronic sacroiliac joint pain and provided lasting improvements compared with conservative management. Our findings suggest that minimally invasive sacroiliac joint arthrodesis may be a reasonable option for patients with sacroiliac joint pain not responsive to 6 months of conservative management.

Appendix

 The details on the study design are available with the online version of this article as a data supplement at [jbjs.org](http://links.lww.com/JBJS/F144) (<http://links.lww.com/JBJS/F144>). ■

Julius Dengler, MD¹⁻³
Djaya Kools, MD⁴
Robert Pflugmacher, MD⁵
Alessandro Gasbarrini, MD⁶
Domenico Prestamburgo, MD⁷
Paolo Gaetani, MD⁸
Daniel Cher, MD⁹

Eddie Van Eeckhoven, PharmD¹⁰
Mårten Annertz, MD, PhD¹¹
Bengt Stuesson, MD, PhD¹²

¹Department of Neurosurgery, Charité-Universitaetsmedizin Berlin, Berlin, Germany

²Brandenburg Medical School Theodor Fontane, Campus Bad Saarow, Bad Saarow, Germany

³Department of Neurosurgery, Helios Clinic, Bad Saarow, Germany

⁴Department of Neurosurgery, Onze-Lieve-Vrouw Hospital Aalst, Aalst, Belgium

⁵Department of Orthopedics and Traumatology, University Hospital Bonn, Bonn, Germany

⁶Instituto Ortopedico Rizzoli di Bologna, Bologna, Italy

⁷Department of Orthopedics and Traumatology, ASST Ovest Milanese-Ospedale di Legnano, Legnano, Italy

⁸Department of Neurosurgery, Policlinico S. Matteo, Pavia, Italy

⁹SI-BONE, Inc., Santa Clara, California

¹⁰Eeckhoven bvba, Kontich, Belgium

¹¹Department of Radiology, Skåne University Hospital, Lund, Sweden

¹²Department of Orthopedics, Aleris, Ängelholm Hospital, Ängelholm, Sweden

E-mail address for J. Dengler: julius.dengler@charite.de

E-mail address for D. Kools: djaya.kools@olvz-aalst.be

E-mail address for R. Pflugmacher: robert.pflugmacher@ukb.uni-bonn.de

E-mail address for A. Gasbarrini: gasbarrini@me.com

E-mail address for D. Prestamburgo: prestamburgo@gmail.com

E-mail address for P. Gaetani: p.gaetani@smatteo.pv.it

E-mail address for D. Cher: dcher@si-bone.com

E-mail address for E. Van Eeckhoven: evaneeckhoven@yahoo.com

E-mail address for M. Annertz: marten.annertz@med.lu.se

E-mail address for B. Stuesson: stuesson.bengt@gmail.com

ORCID iD for J. Dengler: [0000-0002-6698-8600](https://orcid.org/0000-0002-6698-8600)

ORCID iD for D. Kools: [0000-0003-4180-3072](https://orcid.org/0000-0003-4180-3072)

ORCID iD for R. Pflugmacher: [0000-0002-5699-349X](https://orcid.org/0000-0002-5699-349X)

ORCID iD for A. Gasbarrini: [0000-0002-9575-4061](https://orcid.org/0000-0002-9575-4061)

ORCID iD for D. Prestamburgo: [0000-0002-0234-5497](https://orcid.org/0000-0002-0234-5497)

ORCID iD for P. Gaetani: [0000-0003-1415-9365](https://orcid.org/0000-0003-1415-9365)

ORCID iD for D. Cher: [0000-0002-3747-7879](https://orcid.org/0000-0002-3747-7879)

ORCID iD for E. Van Eeckhoven: [0000-0001-6677-0321](https://orcid.org/0000-0001-6677-0321)

ORCID iD for M. Annertz: [0000-0001-9429-0851](https://orcid.org/0000-0001-9429-0851)

ORCID iD for B. Stuesson: [0000-0001-6477-5794](https://orcid.org/0000-0001-6477-5794)

References

1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P,

Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Deneghardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC,

- Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipschultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabwajano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman K, O'Donnell M, O'Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De León FR, Ronfani L, Room R, Rosenfeld LC, Rushon L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shrivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor JW, Thomas B, Thomson WM, Thurston GD, Teyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbiris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012 Dec 15;380(9859):2163-96.
2. Hudson TJ, Edlund MJ, Steffick DE, Tripathi SP, Sullivan MD. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. *J Pain Symptom Manage*. 2008 Sep;36(3):280-8. Epub 2008 Jul 10.
3. Volkow ND. America's addiction to opioids: heroin and prescription drug abuse. 2014 May 14. <https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2014/americas-addiction-to-opioids-heroin-prescription-drug-abuse>. Accessed 2018 Oct 15.
4. Bernard TN Jr, Kirkaldy-Willis WH. Recognizing specific characteristics of non-specific low back pain. *Clin Orthop Relat Res*. 1987 Apr;217:266-80.
5. Sembrano JN, Polly DW Jr. How often is low back pain not coming from the back? *Spine (Phila Pa 1976)*. 2009 Jan 1;34(1):E27-32.
6. Schwarzer AC, Aprill CN, Bogduk N. The sacroiliac joint in chronic low back pain. *Spine (Phila Pa 1976)*. 1995 Jan 1;20(1):31-7.
7. DePalma MJ, Ketchum JM, Saullo TR. Etiology of chronic low back pain in patients having undergone lumbar fusion. *Pain Med*. 2011 May;12(5):732-9. Epub 2011 Apr 11.
8. Stark JG, Fuentes JA, Fuentes TI, Idemilli C. The history of sacroiliac joint arthrodesis: a critical review and introduction of a new technique. *Curr Orthop Pract*. 2011 Nov;22(6):545-57.
9. Polly DW, Swofford J, Whang PG, Frank CJ, Glaser JA, Limoni RP, Cher DJ, Wine KD, Sembrano JN; INSITE Study Group. Two-year outcomes from a randomized controlled trial of minimally invasive sacroiliac joint fusion vs. non-surgical management for sacroiliac joint dysfunction. *Int J Spine Surg*. 2016 Aug 23;10:28.
10. Stuesson B, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Dengler J. Six-month outcomes from a randomized controlled trial of minimally invasive SI joint fusion with triangular titanium implants vs conservative management. *Eur Spine J*. 2017 Mar;26(3):708-19. Epub 2016 May 14.
11. Duhon BS, Bitan F, Lockstadt H, Kovalsky D, Cher D, Hillen T; SIFI Study Group. Triangular titanium implants for minimally invasive sacroiliac joint fusion: 2-year follow-up from a prospective multicenter trial. *Int J Spine Surg*. 2016 Apr 20;10:13.
12. Rudolf L. Sacroiliac joint arthrodesis-MIS technique with titanium implants: report of the first 50 patients and outcomes. *Open Orthop J*. 2012;6:495-502. Epub 2012 Nov 30.
13. Cummings J Jr, Capobianco RA. Minimally invasive sacroiliac joint fusion: one-year outcomes in 18 patients. *Ann Surg Innov Res*. 2013 Sep 16;7(1):12.
14. Gaetani P, Miotti D, Risso A, Bettaglio R, Bongetta D, Custodi V, Silvani V. Percutaneous arthrodesis of sacro-iliac joint: a pilot study. *J Neurosurg Sci*. 2013 Dec;57(4):297-301.
15. Sachs D, Capobianco R, Cher D, Holt T, Gundanna M, Graven T, Shamie AN, Cummings J Jr. One-year outcomes after minimally invasive sacroiliac joint fusion with a series of triangular implants: a multicenter, patient-level analysis. *Med Devices (Auckl)*. 2014 Aug 28;7:299-304.
16. Ledonio CGT, Polly DW Jr, Swiontkowski MF. Minimally invasive versus open sacroiliac joint fusion: are they similarly safe and effective? *Clin Orthop Relat Res*. 2014 Jun;472(6):1831-8.
17. Smith AG, Capobianco R, Cher D, Rudolf L, Sachs D, Gundanna M, Kleiner J, Mody MG, Shamie AN. Open versus minimally invasive sacroiliac joint fusion: a multicenter comparison of perioperative measures and clinical outcomes. *Ann Surg Innov Res*. 2013 Oct 30;7(1):14.
18. Vanaclocha V, Herrera JM, Sáiz-Sapena N, Rivera-Paz M, Verdú-López F. Minimally invasive sacroiliac joint fusion, radiofrequency denervation, and conservative management for sacroiliac joint pain: 6-year comparative case series. *Neurosurgery*. 2018 Jan 1;82(1):48-55.
19. Dengler JD, Kools D, Pflugmacher R, Gasbarrini A, Prestamburgo D, Gaetani P, van Eeckhoven E, Cher D, Stuesson B. 1-year results of a randomized controlled trial of conservative management vs. minimally invasive surgical treatment for sacroiliac joint pain. *Pain Physician*. 2017 Sep;20(6):537-50.
20. Mens JM, Vleeming A, Snijders CJ, Koes BW, Stam HJ. Reliability and validity of the active straight leg raise test in posterior pelvic pain since pregnancy. *Spine (Phila Pa 1976)*. 2001 May 15;26(10):1167-71.
21. Fairbank JC, Pynsent PB. The Oswestry Disability Index. *Spine (Phila Pa 1976)*. 2000 Nov 15;25(22):2940-52; discussion 2952.
22. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy*. 1990 Dec;16(3):199-208.
23. Zung WW, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic. Further validation of the SDS. *Arch Gen Psychiatry*. 1965 Dec;13(6):508-15.
24. R: A language and environment for statistical computing. Vienna: R Core Team; 2013.
25. Dengler J, Duhon B, Whang P, Frank C, Glaser J, Stuesson B, Garfin S, Cher D, Rendahl A, Polly D; INSITE, iMIA, SIFI Study Groups. Predictors of outcome in conservative and minimally invasive surgical management of pain originating from the sacroiliac joint: a pooled analysis. *Spine (Phila Pa 1976)*. 2017 Nov 1;42(21):1664-73.
26. Rudolf L, Capobianco R. Five-year clinical and radiographic outcomes after minimally invasive sacroiliac joint fusion using triangular implants. *Open Orthop J*. 2014 Oct 17;8:375-83.
27. Cher DJ, Reckling WC, Capobianco RA. Implant survivorship analysis after minimally invasive sacroiliac joint fusion using the iFuse Implant System®. *Med Devices (Auckl)*. 2015 Nov 23;8:485-92.
28. Cher D, Wroe K, Reckling WC, Yerby S. Postmarket surveillance of 3D-printed implants for sacroiliac joint fusion. *Med Devices (Auckl)*. 2018 Sep 28;11:337-43.
29. Martin BI, Mirza SK, Flum DR, Wickizer TM, Heagerty PJ, Lenkoski AF, Deyo RA. Repeat surgery after lumbar decompression for herniated disc: the quality implications of hospital and surgeon variation. *Spine J*. 2012 Feb;12(2):89-97. Epub 2011 Dec 21.
30. Strömqvist B, Fritzell P, Hägg G, Jönsson B, Sandén B; Swedish Society of Spinal Surgeons. Swespine: the Swedish spine register: the 2012 report. *Eur Spine J*. 2013 Apr;22(4):953-74.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-83.
32. Vleeming A, Albert HB, Östgaard HC, Stuesson B, Stuge B. European guidelines for the diagnosis and treatment of pelvic girdle pain. *Eur Spine J*. 2008 Jun;17(6):794-819. Epub 2008 Feb 8.
33. Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. *Spine (Phila Pa 1976)*. 2005 Jun 1;30(11):1331-4.
34. Copay AG, Cher DJ. Is the Oswestry Disability Index a valid measure of response to sacroiliac joint treatment? *Qual Life Res*. 2016 Feb;25(2):283-92. Epub 2015 Aug 6.